My research is based on the application of cancer proteomics to:
- identify biomarkers of response to anticancer therapy
- identify novel therapy targets or therapy strategies
- investigate the molecular mechanism of action of novel anticancer agents
V C Hodgkinson, V Agarwal, D ELFadl, J N Fox, P L McManus, T K Mahapatra, P J Kneeshaw, P J Drew, M J Lind, L Cawkwell. Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer. Journal of Proteomics 75: 2745-2752 (2012).
V C Hodgkinson, D ELFadl, V Agarwal, V Garimella, C Russell, E D Long, J N Fox, P L McManus, T K Mahapatra, P J Kneeshaw, P J Drew, M J Lind, L Cawkwell. Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID? Journal of Proteomics 75: 1276-1283 (2012).
V C Hodgkinson, D ELFadl, P J Drew, M J Lind,L Cawkwell. Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis. Journal of Proteomics. 74: 698-703 (2011).
V Agarwal, M J Lind, L Cawkwell. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand? Cancer Treatment Reviews 37: 533-542 (2011).
L Smith, O Qutob, M B Watson, A W Beavis, D Potts, K J Welham, V Garimella, M J Lind, P J Drew, L Cawkwell. Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome? Neoplasia 11:1194-1207 (2009).
Graduate Research Director (Postgraduate Medical Institute).
Chair, Humber Bridge Research Ethics Committee (NHS Health Research Authority).